Trial Profile
The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Therapeutic Use
- Acronyms MONDOAC AND KIDOAC
- 19 Oct 2021 Results (n=152)from KIDOAC assessing the inter-and intra-variability of drug concentrations in patients treated with DOACs in daily practice, published in the Journal of Thrombosis and Haemostasis
- 14 Mar 2020 Results, assessing treatment satisfaction and patient concerns in patients who Switching from vitamin K antagonists to direct oral anticoagulants, published in the Journal of Thrombosis and Haemostasis
- 08 Mar 2018 New trial record